Finding new DNA markers to predict cancer risk in low-grade oral lesions
Discovery of New DNA Methylation Biomarkers for Predicting the Malignant Outcome of Low-Grade Oral Dysplasia
This study is looking at changes in DNA from early mouth lesions to see if they might turn into cancer, helping doctors find out which patients need closer monitoring for oral cancer risk.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10808193 on NIH RePORTER |
What this research studies
This research focuses on identifying DNA methylation changes in oral premalignant lesions, which can indicate the risk of developing oral squamous cell carcinoma (OSCC). By analyzing the genetic material from these lesions, researchers aim to distinguish between those that will remain stable and those that may progress to cancer. The study employs a whole-genome approach to discover specific regions of DNA that are differentially methylated in progressive versus static lesions. This could lead to the development of a biomarker that helps in early detection and management of patients at risk for OSCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with low-grade oral dysplasia who are at risk of progression to oral squamous cell carcinoma.
Not a fit: Patients with high-grade dysplasia or those already diagnosed with oral squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a reliable biomarker for early identification of patients at high risk for developing oral cancer, enabling timely intervention.
How similar studies have performed: Previous studies have shown promise in identifying DNA methylation changes in cancer progression, suggesting that this approach may yield valuable insights.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Tsai, Robert Y — Texas A&m University Health Science Ctr
- Study coordinator: Tsai, Robert Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.